Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.3K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.3K
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

1.9K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.9K
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

2.3K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
2.3K
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

2.8K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
2.8K
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

2.1K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
2.1K
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

2.5K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Applying Deep-Learning-Driven <i>De Novo</i> Design to Hit Identification: A Case Study on A<sub>2A</sub> Adenosine Receptor Antagonists.

Journal of medicinal chemistry·2026
Same author

PIP4K2A/2B inhibitor suppresses tumor growth in a xenograft model of NSCLC.

iScience·2026
Same author

Identification of 2-Substituted-3-Hydroxy-2,3-Dihydroquinazolin-4(1H) Ones as Cell-Active Inhibitors of KDM4A Lysine Demethylase.

ChemMedChem·2026
Same author

Discovery of a Novel Lung-Restricted ALK5 Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis.

Journal of medicinal chemistry·2026
Same author

Structural basis for high-affinity inhibitor binding to lipid kinases PIP4K2A and PIP4K2B.

Acta crystallographica. Section D, Structural biology·2026
Same author

15-Hydroxyeicosatetraenoic Acid and GPR39 Together Orchestrate Coronary Autoregulation: A Comprehensive Metabolomic Analysis.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: May 5, 2026

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
07:56

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

Published on: August 11, 2021

2.6K

Triple monoamine uptake inhibitors.

Anna Maria Capelli1, Fabrizio Micheli

  • 1Computational Chemistry Unit - CRDD, Chiesi Farmaceutici S.p.A., Largo F. Belloli 11A, 43100 Parma, Italy.

Pharmaceutical Patent Analyst
|November 19, 2013
PubMed
Summary

This review explores molecules that block the reuptake of dopamine, norepinephrine, and serotonin. These compounds offer potential for treating depression, pain, and substance dependence.

Area of Science:

  • Neuroscience and Pharmacology
  • Medicinal Chemistry

Background:

  • Agents affecting monoamine neurotransmitter reuptake are crucial for treating depression, pain, and dependence.
  • Recent years have seen an expansion in chemical diversity for these agents.

Purpose of the Study:

  • To provide an organic overview of molecules that simultaneously inhibit the reuptake of dopamine, norepinephrine, and serotonin.
  • To explore novel therapeutic applications and chemical templates.

Main Methods:

  • Literature review of scientific publications and patents.
  • Analysis of chemical structures and their pharmacological profiles.
  • Categorization of molecules based on their multi-target reuptake inhibition.

Main Results:

More Related Videos

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
11:44

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

2.2K
Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram
12:21

Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram

Published on: November 27, 2016

15.5K

Related Experiment Videos

Last Updated: May 5, 2026

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
07:56

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

Published on: August 11, 2021

2.6K
Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
11:44

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

2.2K
Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram
12:21

Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram

Published on: November 27, 2016

15.5K
  • Identification of various chemical scaffolds targeting all three major monoamine transporters.
  • Discussion of structure-activity relationships for dual and triple reuptake inhibitors.
  • Overview of preclinical and clinical studies on these compounds.

Conclusions:

  • Molecules inhibiting the reuptake of all three monoamine neurotransmitters represent a promising area for drug discovery.
  • These multi-acting agents hold potential for treating complex conditions like treatment-resistant depression and addiction.
  • Further research into novel chemical templates is warranted to optimize efficacy and safety profiles.